Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Notes Payables (2016 - 2022)

IGC Pharma (IGC) has disclosed Notes Payables for 12 consecutive years, with $3000.0 as the latest value for Q2 2022.

  • On a quarterly basis, Notes Payables changed 0.0% to $3000.0 in Q2 2022 year-over-year; TTM through Jun 2022 was $3000.0, a 0.0% change, with the full-year FY2022 number at $3000.0, down 99.01% from a year prior.
  • Notes Payables was $3000.0 for Q2 2022 at IGC Pharma, roughly flat from $3000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.8 million in Q1 2018 to a low of $3000.0 in Q2 2021.
  • A 5-year average of $401062.5 and a median of $50000.0 in 2019 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: surged 508.0% in 2021, then tumbled 99.01% in 2022.
  • IGC Pharma's Notes Payables stood at $1.8 million in 2018, then crashed by 97.22% to $50000.0 in 2019, then soared by 404.0% to $252000.0 in 2020, then plummeted by 98.81% to $3000.0 in 2021, then changed by 0.0% to $3000.0 in 2022.
  • Per Business Quant, the three most recent readings for IGC's Notes Payables are $3000.0 (Q2 2022), $3000.0 (Q1 2022), and $3000.0 (Q4 2021).